A Phase 2 interventional study of VVN539 Ophthalmic Solution 0.02% and VVN539 Ophthalmic Solution 0.04% in Glaucoma, Open-Angle, sponsored by VivaVision Biotech, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-17.
Sponsored by VivaVision Biotech, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.
Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 163rd largest by enrollment of the 279 interventional ones that give a count, is one of 13 that started in 2022, is one of 76 in phase 2, and was the 275th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:
Tavo Biotherapeutics · Sites in United States
Ages 18+
Brett King · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 20–79 · Healthy volunteers
YS Life Science Co., Ltd. · Sites in United States, India
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
348 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 99 · Phase 3 58 · Phase 4 36
First in 1976; this study’s year is marked. 13 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 84 across the 279 interventional studies, 100 across the 57 observational. Of the 260 that completed or were terminated, 117 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
228 of 348 have an industry lead sponsor. The 10 most frequent:
VivaVision Biotech, Inc is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
VivaVision Biotech, Inc has 1 study filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
24 of the studies in Glaucoma, Open-Angle with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05695027Phase 3Columbia UniversityNicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study | 2027-08 |
| NCT07661329Phase 3YS Life Science Co., Ltd.A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension | 2027-11-01 |
| NCT05626426Stanford UniversityElectrical Stimulation for the Treatment of Optic Neuropathies | 2026-12 |
| NCT05626491Stanford UniversityElectrical Stimulation for the Treatment of Glaucoma | 2026-12 |
| NCT05506423Iantrek, Inc.Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes | 2026-12 |
Add all 24 to your calendar (.ics) → With an account.
Among the 348 studies in Glaucoma, Open-Angle with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, parallel-comparison, multi-center, double-masked, randomized, vehicle-controlled dose-response study assessing the safety and ocular hypotensive efficacy of VVN539 in subjects with POAG or OHT. Three different dosing regimens (once a day [q.d.] in the morning, q.d. in the evening and twice a day [b.i.d.]) will be tested for 7-9 days, each.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VVN539 Ophthalmic Solution 0.02%
Drug: VVN539 Ophthalmic Solution 0.02%
VVN539 Ophthalmic Solution 0.04%
Drug: VVN539 Ophthalmic Solution 0.04%
VVN539 Ophthalmic Solution Vehicle
Drug: VVN539 Ophthalmic Solution Vehicle
Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
Mean Intraocular Pressure
mmHg
Time frame: 8AM, 10AM, and 4PM at Day 7; Day 14 and Day 21
Mean Change in Intraocular Pressure From Baseline
mmHg
Time frame: 8AM, 10AM, and 4PM at Day 7; Day 14 and Day 21
| Milestone | VVN539 Ophthalmic Solution 0.02% | VVN539 Ophthalmic Solution 0.04% | VVN539 Ophthalmic Solution Vehicle |
|---|---|---|---|
| Started | 23 | 22 | 23 |
| Completed | 20 | 20 | 23 |
| Not completed | 3 | 2 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Investigational product lot exchange | 1 | 1 | 0 |
mmHg
| mmHg | VVN539 Ophthalmic Solution 0.02% | VVN539 Ophthalmic Solution 0.04% | VVN539 Ophthalmic Solution Vehicle |
|---|---|---|---|
| 0800 AM Day 7 | 21.8 ± 4.6 | 20.5 ± 2.5 | 23.4 ± 3.9 |
| 1000 AM Day 7 | 19.7 ± 4.7 | 19.0 ± 2.8 | 22.0 ± 3.1 |
| 0400 PM Day 7 | 19.1 ± 4.1 | 18.1 ± 2.6 | 21.7 ± 2.9 |
| 0800 AM Day 14 | 21.1 ± 5.0 | 19.6 ± 3.9 | 23.1 ± 3.5 |
| 1000 AM Day 14 | 19.9 ± 5.1 | 18.2 ± 4.3 | 22.1 ± 3.0 |
| 0400 PM Day 14 | 19.7 ± 5.2 | 18.0 ± 2.8 | 22.0 ± 3.9 |
| 0800 AM Day 21 | 19.7 ± 3.6 | 19.2 ± 2.8 | 23.4 ± 3.9 |
| 1000 AM Day 21 | 19.2 ± 5.0 | 19.1 ± 3.3 | 22.6 ± 3.2 |
| 0400 PM Day 21 | 18.7 ± 5.2 | 18.8 ± 3.0 | 21.7 ± 3.7 |
mmHg
| mmHg | VVN539 Ophthalmic Solution 0.02% | VVN539 Ophthalmic Solution 0.04% | VVN539 Ophthalmic Solution Vehicle |
|---|---|---|---|
| 0800 AM Day 7 | -3.6 ± 4.1 | -4.1 ± 2.7 | -2.0 ± 2.8 |
| 1000 AM Day 7 | -5.3 ± 4.2 | -5.0 ± 3.0 | -2.3 ± 3.0 |
| 0400 PM Day 7 | -3.3 ± 3.5 | -4.6 ± 2.6 | -1.3 ± 2.2 |
| 0800 AM Day 14 | -4.3 ± 4.3 | -5.0 ± 4.0 | -2.2 ± 2.7 |
| 1000 PM Day 14 | -5.1 ± 4.2 | -5.8 ± 3.6 | -2.1 ± 2.3 |
| 0400 PM Day 14 | -2.7 ± 4.6 | -4.8 ± 3.3 | -0.9 ± 3.5 |
| 0800 AM Day 21 | -5.7 ± 2.7 | -5.4 ± 2.8 | -2.0 ± 3.3 |
| 1000 AM Day 21 | -5.7 ± 3.9 | -5.0 ± 3.7 | -1.5 ± 2.4 |
| 0400 PM Day 21 | -3.7 ± 4.3 | -3.9 ± 2.8 | -1.2 ± 3.4 |
Collected over 21 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VVN539 Ophthalmic Solution 0.02% | 0/23 (0%) | 0/23 (0%) | 11/23 (47.8%) |
| VVN539 Ophthalmic Solution 0.04% | 0/22 (0%) | 0/22 (0%) | 10/22 (45.5%) |
| VVN539 Ophthalmic Solution Vehicle | 0/23 (0%) | 0/23 (0%) | 1/23 (4.3%) |
| Event | VVN539 Ophthalmic Solution 0.02% | VVN539 Ophthalmic Solution 0.04% | VVN539 Ophthalmic Solution Vehicle |
|---|---|---|---|
| Conjunctival hyperaemiaEye disorders | 11/23 | 10/22 | 1/23 |
| Ocular hyperaemiaEye disorders | 3/23 | 5/22 | 0/23 |
| Eye painEye disorders | 1/23 | 3/22 | 0/23 |
| Eye irritationEye disorders | 1/23 | 2/22 | 0/23 |
| Vision blurredEye disorders | 1/23 | 2/22 | 0/23 |
| Age, Categorical(Participants) | VVN539 Ophthalmic Solution 0.02% | VVN539 Ophthalmic Solution 0.04% | VVN539 Ophthalmic Solution Vehicle | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 9 | 9 | 23 |
| >=65 years | 18 | 13 | 14 | 45 |
| Age, Continuous(years) | VVN539 Ophthalmic Solution 0.02% | VVN539 Ophthalmic Solution 0.04% | VVN539 Ophthalmic Solution Vehicle | Total |
|---|---|---|---|---|
| Mean | 69.1 ± 9.0 | 65.1 ± 13.4 | 64.7 ± 16.4 | 66.3 ± 13.2 |
| Sex: Female, Male(Participants) | VVN539 Ophthalmic Solution 0.02% | VVN539 Ophthalmic Solution 0.04% | VVN539 Ophthalmic Solution Vehicle | Total |
|---|---|---|---|---|
| Female | 12 | 9 | 12 | 33 |
| Male | 11 | 13 | 11 | 35 |
| Ethnicity (NIH/OMB)(Participants) | VVN539 Ophthalmic Solution 0.02% | VVN539 Ophthalmic Solution 0.04% | VVN539 Ophthalmic Solution Vehicle | Total |
|---|---|---|---|---|
| Hispanic or Latino | 6 | 2 | 3 | 11 |
| Not Hispanic or Latino | 17 | 20 | 20 | 57 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | VVN539 Ophthalmic Solution 0.02% | VVN539 Ophthalmic Solution 0.04% | VVN539 Ophthalmic Solution Vehicle | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 0 | 4 |
| White | 18 | 19 | 23 | 60 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 0 | 2 |
| Region of Enrollment(participants) | VVN539 Ophthalmic Solution 0.02% | VVN539 Ophthalmic Solution 0.04% | VVN539 Ophthalmic Solution Vehicle | Total |
|---|---|---|---|---|
| United States | 23 | 22 | 23 | 68 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2022 to primary completion in Dec 2022, 5 months.
Results were first posted in Jan 2024, 1 year after primary completion.
Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 5 months is below that.
Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VivaVision Biotech, Inc